Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles

• Published in: Theranostics 2018-01, Vol.8 (12), p.3416-3436
• Main Authors: Johnsen, Kasper Bendix, Bak, Martin, Kempen, Paul Joseph, Melander, Fredrik, Burkhart, Annette, Thomsen, Maj Schneider, Nielsen, Morten Schallburg, Moos, Torben, Andresen, Thomas Lars
• Format: Article
• Language: English
• Subjects: Research Paper
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.25228

The ability to treat invalidating neurological diseases is impeded by the presence of the blood-brain barrier (BBB), which inhibits the transport of most blood-borne substances into the brain parenchyma. Targeting the transferrin receptor (TfR) on the surface of brain capillaries has been a popular strategy to give a preferential accumulation of drugs or nanomedicines, but several aspects of this targeting strategy remain elusive. Here we report that TfR-targeted gold nanoparticles (AuNPs) can accumulate in brain capillaries and further transport across the BBB to enter the brain parenchyma. We characterized our targeting strategy both in vitro using primary models of the BBB and in vivo using quantitative measurements of gold accumulation by inductively-coupled plasma-mass spectrometry together with morphological assessments using light microscopy after silver enhancement and transmission electron microscopy with energy-dispersive X-ray spectroscopy. We find that the uptake capacity is significantly modulated by the affinity and valency of the AuNP-conjugated antibodies. Specifically, antibodies with high and low affinities mediate a low and intermediate uptake of AuNPs into the brain, respectively, whereas a monovalent (bi-specific) antibody improves the uptake capacity remarkably. Our findings indicate that monovalent ligands may be beneficial for obtaining transcytosis of TfR-targeted nanomedicines across the BBB, which is relevant for future design of nanomedicines for brain drug delivery.